Please note: Work is currently underway to update content available on this site.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Publication #8299
Reference
Name
National Patient Safety Alert – Discontinuation of Kay-Cee-L® (Potassium Chloride 375mg/5ml) (Potassium Chloride 5mmol/5ml) syrup
Categories
Scottish Government
Organization
Scottish Government Health and Social Care Department
Keywords
NHS
Scotland
Health Boards
National Patient Safety Alert
Shortages
Description
This NatPSA supersedes a previously issued NatPSA.
Kay-Cee-L® (potassium chloride 5mmol/5ml) syrup will be discontinued from late November 2024 due to manufacturing and commercial issues.
Sando-K® (potassium bicarbonate 400mg and potassium chloride 600mg) effervescent tablets remain available and can support a full increase in demand. One effervescent tablet contains 12mmol potassium.
Unlicensed potassium chloride oral solutions manufactured within the UK are available via Specials manufacturers, lead times vary.
Care is needed to ensure selection of the most appropriate oral potassium supplement and delivery of the correct dosage.
Contact Name
Irene Fazakerley
Contact Email
Contact Address
Contact Phone
Created
2024-10-21 09:50:00
Click to go back to homepage